Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review.
Malignant pericardial effusion (MPCE) is a common complication of advanced malignant tumors, and interferes severely with patient prognosis and quality of life. The standard treatment for this complication is intracavitary perfusion of chemotherapeutic drugs, which is limited by unsatisfactory therapeutic effects and serious adverse events. We report a patient with MPCE who was treated with bevacizumab by pericardial perfusion, resulting in a complete response. This case supports the use of intrapericardial bevacizumab as a potential treatment for MPCE.
Weifang Medical University, Weifang, People's Republic of China ; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, People's Republic of China.
Dawei
D
Chen
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, People's Republic of China.
Yan
Y
Zhang
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, People's Republic of China.
Fang
F
Shi
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, People's Republic of China.
Minghuan
M
Li
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, People's Republic of China.
Hui
H
Zhu
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, People's Republic of China.
Li
L
Kong
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, People's Republic of China.
Jinming
J
Yu
bevacizumab; lung cancer; malignant pericardial effusion